Bardelli Silvana, Moccetti Marco
Swiss Institute for Regenerative Medicine, Cardiocentro Ticino Foundation, Via Tesserete 48, 6900, Lugano, Switzerland.
Cardiology Department, Cardiocentro Ticino Foundation, Via Tesserete 48, 6900, Lugano, Switzerland.
Adv Exp Med Biol. 2016;951:163-178. doi: 10.1007/978-3-319-45457-3_14.
Cardiovascular diseases, including heart failure, are the most frequent cause of death annually, even higher than any other pathologies. Specifically, patients who suffer from myocardial infarction may encounter adverse remodeling processes of the heart that can ultimately lead to heart failure. Prognosis of patients affected by heart failure is very poor with 5-year mortality close to 50 %. Despite the impressive progress in the clinical treatment of heart failure in recent years, heart transplantation is still required to avoid death as the result of the inexorable decline in cardiac function. Unfortunately, the availability of donor human hearts for transplantation largely fails to cover the number of potential recipient requests. From this urgent unmet clinical need the interest in stem cell applications for heart regeneration made its start, and has rapidly grown in the last decades. Indeed, the discovery and application of stem and progenitor cells as therapeutic agents has raised substantial interest with the objective of reversing these processes, and ultimately inducing cardiac regeneration. In this scenario, the role of biobanking may play a remarkable role to provide cells at the right time according to the patient's clinical needs, mostly for autologous use in the acute setting of myocardial infarction, largely reducing the time needed for cell preparation and expansion before administration.
心血管疾病，包括心力衰竭，是每年最常见的死亡原因，甚至高于任何其他疾病。具体而言，患有心肌梗死的患者可能会经历心脏的不良重塑过程，最终可能导致心力衰竭。心力衰竭患者的预后非常差，5年死亡率接近50%。尽管近年来心力衰竭的临床治疗取得了令人瞩目的进展，但由于心脏功能不可避免地下降，仍需要进行心脏移植以避免死亡。不幸的是，用于移植的供体心脏的可获得性远远无法满足潜在受体的需求数量。出于这种迫切未满足的临床需求，对干细胞应用于心脏再生的兴趣由此开始，并在过去几十年中迅速增长。事实上，干细胞和祖细胞作为治疗剂的发现和应用引起了人们极大的兴趣，其目标是逆转这些过程，并最终诱导心脏再生。在这种情况下，生物样本库的作用可能非常显著，能够根据患者的临床需求在合适的时间提供细胞，主要用于心肌梗死急性期自体使用，大大减少给药前细胞制备和扩增所需的时间。
